1. Home
  2. LEGN vs CRDO Comparison

LEGN vs CRDO Comparison

Compare LEGN & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CRDO
  • Stock Information
  • Founded
  • LEGN 2014
  • CRDO 2008
  • Country
  • LEGN United States
  • CRDO Cayman Islands
  • Employees
  • LEGN N/A
  • CRDO N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CRDO Semiconductors
  • Sector
  • LEGN Health Care
  • CRDO Technology
  • Exchange
  • LEGN Nasdaq
  • CRDO Nasdaq
  • Market Cap
  • LEGN 7.0B
  • CRDO 7.3B
  • IPO Year
  • LEGN 2020
  • CRDO 2022
  • Fundamental
  • Price
  • LEGN $31.08
  • CRDO $59.07
  • Analyst Decision
  • LEGN Strong Buy
  • CRDO Strong Buy
  • Analyst Count
  • LEGN 13
  • CRDO 10
  • Target Price
  • LEGN $79.42
  • CRDO $68.00
  • AVG Volume (30 Days)
  • LEGN 1.6M
  • CRDO 3.6M
  • Earning Date
  • LEGN 05-13-2025
  • CRDO 05-28-2025
  • Dividend Yield
  • LEGN N/A
  • CRDO N/A
  • EPS Growth
  • LEGN N/A
  • CRDO N/A
  • EPS
  • LEGN N/A
  • CRDO 0.03
  • Revenue
  • LEGN $728,303,000.00
  • CRDO $327,532,000.00
  • Revenue This Year
  • LEGN $65.96
  • CRDO $125.51
  • Revenue Next Year
  • LEGN $52.55
  • CRDO $58.82
  • P/E Ratio
  • LEGN N/A
  • CRDO $1,923.01
  • Revenue Growth
  • LEGN 112.46
  • CRDO 99.38
  • 52 Week Low
  • LEGN $29.27
  • CRDO $16.98
  • 52 Week High
  • LEGN $60.87
  • CRDO $86.69
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.41
  • CRDO 72.89
  • Support Level
  • LEGN $30.25
  • CRDO $45.65
  • Resistance Level
  • LEGN $33.30
  • CRDO $49.44
  • Average True Range (ATR)
  • LEGN 1.53
  • CRDO 2.61
  • MACD
  • LEGN -0.18
  • CRDO 1.81
  • Stochastic Oscillator
  • LEGN 26.21
  • CRDO 94.17

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CRDO Credo Technology Group Holding Ltd

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

Share on Social Networks: